Regulatory laws and policies create targeted incentives for innovation across pharmaceuticals, biological products, medical devices, combination products, and advanced therapy medicinal products, including cell and gene therapies and tissue‑based products. These incentives take many forms, such as streamlined regulatory procedures, tax and reimbursement incentives, and market‑based rewards including exclusivity, patent term extensions, and priority review vouchers. Our lawyers help clients identify, pursue, and maximize these incentives throughout development and commercialization. 

Recognizing that regulators in the U.S., EU, and other jurisdictions promote regulatory convergence while operating under distinct legal and policy regimes, we collaborate seamlessly across borders. We understand how these regimes intersect and how to strategically position products to benefit from multiple pathways, both efficiently and at scale, for the benefit of patients. 

Our integrated approach minimizes duplication and divergence during development, aligns regulatory strategies to capture cross-border opportunities, and allows us to successfully advocate before national and supranational authorities.